RXRX Stock Price Today (April 2026) — Recursion Pharmaceuticals, Inc. Analysis & Key Metrics 2026-04-15
Recursion Pharmaceuticals, Inc. (RXRX) is trading at $3.69, up 4.10% today (as of April 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $6.71 (82.1% upside).
- Volatility remains elevated (51.87% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.82% YoY) alongside significant competitive pressures.
RXRX Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Recursion Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $974.88M
P/E Ratio
Forward P/E: -3.65
Revenue Growth
Year over Year
Analyst Target
+82.1% upside potential
Key Investor Questions About RXRX
What investors need to know before buying
Based on current market data, RXRX presents a overbought technical setup with caution warranted fundamentals.
- Technicals say: Overbought (RSI 72.10)
- Fundamentals say: Caution warranted (high leverage concerns)
RXRX's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for RXRX investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $77.97M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, RXRX stock traded between $2.80 and $7.18—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 51.87% annualized volatility and β=0.96, the stock exhibits moderate correlation to market moves—making RXRX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Recursion And Citeline Deepen AI Trial Data Tie For RXRX Investors
Recursion Pharmaceuticals expanded its collaboration with Citeline to integrate real world data into its AI enabled ClinTech Platform. The partnership is aimed at refining clinical trial design and execution by combining Citeline data with Recursion's in house technology. This development is intended to support more precise patient selection and trial planning for NasdaqGS:RXRX. For investors watching NasdaqGS:RXRX, this update comes with the stock at $3.31, after a 6.4% gain over the past...
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
Recursion Pharmaceuticals (RXRX) closed at $3.32 in the latest trading session, marking a -2.06% move from the prior day.
Recursion Pharmaceuticals Inc. (RXRX) Partners with Citeline to Develop AI-Powered ClinTech Platform
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best multibagger penny stocks to invest in. On March 31, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) and Citeline expanded their strategic partnership to further develop the artificial intelligence-enabled ClinTech Platform. The expanded partnership also underscores the company’s commitment to building a more predictive and patient-centered biopharmaceutical ecosystem. It also […]
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
Recursion Pharmaceuticals (RXRX) reached $3.11 at the closing of the latest trading day, reflecting a +1.63% change compared to its last close.
Expanded Citeline Data Partnership and CMO Transition Could Be A Game Changer For Recursion Pharmaceuticals (RXRX)
In March 2026, Citeline announced an expanded strategic partnership with Recursion Pharmaceuticals to integrate Citeline's real-world data and evidence into Recursion’s tech-enabled drug discovery and development platform, aiming to improve clinical trial design, site selection, and decision-making. Recursion also disclosed a leadership transition, with experienced oncology drug developer Vicki Goodman, M.D., set to become Chief Medical Officer in April 2026 as David Mauro, M.D., Ph.D. steps...
2 AI Healthcare Stocks to Buy Right Now
The convergence of two already fantastic industries is creating an incredible opportunity.
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from cap-weighted peers and creates both opportunity and risk that investors need to understand clearly right now. The fund carries over $8 billion in assets across 150+ holdings, ... MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.94, representing a -6.67% change from its previous close.
Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Recent Share Price Weakness And Split Fair Value Views
Event driven snapshot of Recursion Pharmaceuticals Recursion Pharmaceuticals (RXRX) shares have been drawing attention after recent performance data showed a 7% decline over the past month and a 28% decline over the past 3 months, increasing focus on its drug discovery pipeline. See our latest analysis for Recursion Pharmaceuticals. At a share price of $3.17, Recursion’s short term momentum is weak, with a 7 day share price return of a 4.5% decline and a 30 day share price return of a 7.0%...
Frequently Asked Questions
Common investor questions about Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) is currently trading at $3.69. The RSI (14-day) is at 72.1, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "Hold" recommendation. The mean analyst price target of $6.71 implies 82.1% upside from current levels. Volatility is high at 51.9% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Recursion Pharmaceuticals, Inc. (RXRX): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is -3.65. Price-to-Book is 1.45. Price-to-Sales is 22.00. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 7 analysts covering RXRX, the consensus price target is $6.71. This represents a 82.1% upside from the current price of $3.69. The range spans from a low target of $3.00 to a high target of $11.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Recursion Pharmaceuticals, Inc. (RXRX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Recursion Pharmaceuticals, Inc. (RXRX) investors include: 1. High volatility (51.9% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Elevated short interest (34.9% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Recursion Pharmaceuticals, Inc.'s (RXRX) current debt and financial health profile: Total debt stands at $77.97M. The debt-to-equity ratio is 6.89, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 5.50, indicating strong short-term liquidity. The quick ratio is 5.20. The company holds $743.29M in cash and equivalents. Free cash flow is negative at $-208,521,744, which could limit the company's ability to manage debt obligations.